Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Li Q, Feller A, Stussi G. Benz R, et al. Blood Adv. 2020 Aug 11;4(15):3699-3707. doi: 10.1182/bloodadvances.2020002160. Blood Adv. 2020. PMID: 32777066 Free PMC article. Clinical Trial.
Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries.
Benzarti S, Daskalakis M, Feller A, Bacher VU, Schnegg-Kaufmann A, Rüfer A, Holbro A, Schmidt A, Benz R, Solenthaler M, Stussi G, Arndt V, Bonadies N; NICER Working Group. Benzarti S, et al. Among authors: benz r. Cancer Epidemiol. 2019 Apr;59:51-57. doi: 10.1016/j.canep.2019.01.003. Epub 2019 Jan 25. Cancer Epidemiol. 2019. PMID: 30690330
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.
Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides AP, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC; Swiss Group for Clinical Cancer Research (SAKK). Drexler B, et al. Among authors: benz r. Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8. Haematologica. 2019. PMID: 30409796 Free PMC article. Clinical Trial.
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer HP, Sperb R, Stüssi G, Winkler A, Zenhäusern R, Goede JS. Rüfer A, et al. Among authors: benz r. Hemasphere. 2022 Jun 17;6(7):e741. doi: 10.1097/HS9.0000000000000741. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35747588 Free PMC article. No abstract available.
635 results